Moderna (MRNA) Stock Forecast & Price Target
Score
Moderna, Inc. price target
| MRNA | |
|---|---|
| Low | $25.00 |
| Average | $132.70 |
| High | $245.00 |
| Upside vs current price | -40.6% |
The average target of $132.70 is -40.6% versus the current MRNA price of $223.37.
Moderna, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 3 |
| Hold | 15 |
| Sell | 2 |
| Strong sell | 2 |
| Consensus | Hold |
23 analysts cover MRNA.
Moderna, Inc. EPS and revenue estimates
Published annual figures for MRNA on this page are 2026 EPS $-8.42, 2027 EPS $-4.76. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-8.42 | $2.10B |
| 2027 | $-4.76 | $2.43B |
Is Moderna, Inc. a buy or sell?
Of the 23 analysts covering Moderna, Inc., 4 rate it a buy (1 strong buy and 3 buy), 15 rate it a hold, and 4 rate it a sell (2 sell and 2 strong sell).
The MRNA consensus label is Hold, beside 4 buy-side ratings and 4 sell-side ratings.
The average target of $132.70 implies -40.6% versus the current price of $223.37.
The MRNA rating block is 23 published views with a Hold label. It does not tell you whether to buy or sell.
Reading the Moderna, Inc. forecast
A wide spread is the story on MRNA. Targets run from $25.00 to $245.00, with $132.70 as the average.
The gap from the $223.37 price to the MRNA average is -40.6%.
The MRNA rating mix is lopsided rather than split: 4 of 23 analysts are on the buy side, 15 are at hold, and 4 are on the sell side, and the published consensus is Hold.
The latest MRNA actions do not point one way: 3 up and 3 down.
Month by month, the MRNA average target is higher ($183.50) than the quarterly average ($153.30).
the Moderna, Inc. is followed by 23 analysts, so the range matters more than any one target.
Moderna, Inc. forecast questions
What is the MRNA price target?
The published range for MRNA is $25.00 to $245.00, with an average of $132.70. That average is -40.6% versus the current price of $223.37.
Is Moderna, Inc. a buy or sell?
Of the 23 analysts covering Moderna, Inc., 4 rate it a buy, 15 rate it a hold, and 4 rate it a sell. The consensus is Hold, leaving MRNA at 4 buy ratings, 15 holds, and 4 sells.
What is the EPS estimate for Moderna, Inc.?
Analyst EPS estimates for Moderna, Inc.: 2026 $-8.42, 2027 $-4.76.
What is the revenue estimate for Moderna, Inc.?
Analyst revenue estimates for Moderna, Inc.: 2026 $2.10B, 2027 $2.43B.
How many analysts cover MRNA?
23 analysts cover MRNA. Their consensus on MRNA is Hold, across those 23.